Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

被引：15
|
作者：
Liu, Shangde [1 ]
Li, Shanshan [1 ]
Yuan, Duo [1 ]
Wang, Enmao [1 ]
Xie, Roujie [1 ]
Zhang, Weiqi [1 ]
Kong, Yi [2 ]
Zhu, Xiong [1 ]
机构：
[1] China Pharmaceut Univ, Inst Med & Chem, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Sch Life & Technol, Nanjing 210009, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 209卷
关键词：
PAR4; Small-molecule antagonists; Antiplatelet agents; SAR; Structural optimization; BMS-986120; BMS-986141; Preclinical trials; Clinical trials; ACUTE CORONARY SYNDROMES; THROMBIN-RECEPTOR; PLATELET ACTIVATION; THROMBOXANE PRODUCTION; IN-VITRO; INHIBITION; YD-3; AGGREGATION; DISCOVERY; PEPTIDES;
D O I：
10.1016/j.ejmech.2020.112893
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Protease activated receptor 4 (PAR4) is a key target in antiplatelet medication to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth while retaining initial thrombus formation by acting on the late diffusion stage of platelet activation, which may provide a safer alternative than other antiplatelet agents. Currently, research on PAR4 antagonists is of increasing interest in the field of antiplatelet agents. This article provides an overview of the discovery and development of small-molecule antagonists of PAR4 as novel antiplatelet agents, including structure-activity relationship (SAR) analysis, progress of structure and bioassay optimization, and the latest structural and/or clinical information of representative small-molecule antagonists of PAR4. (c) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数：15
相关论文
共 50 条
  • [41] Improved Inhibition of Protease-Activated Receptor 4 (PAR4) with Function-Blocking Antibodies Provides Equivalent Antithrombotic Activity in the Face of the Hyper-Reactive Thr120 PAR4 Variant
    French, Shauna L.
    Thalmann, Claudia
    Machlus, Kellie
    Sleeman, Mark A.
    Hamilton, Justin R.
    BLOOD, 2017, 130
  • [42] Discovery and Optimization of a Novel Series of Competitive and Central Nervous System-Penetrant Protease-Activated Receptor 4 (PAR4) Inhibitors
    Bertron, Jeanette L.
    Duvernay, Matthew T.
    Mitchell, Sidnee G.
    Smith, Shannon T.
    Maeng, Jae G.
    Blobaum, Anna L.
    Davis, Dexter C.
    Meiler, Jens
    Hamm, Heidi E.
    Lindsley, Craig W.
    ACS CHEMICAL NEUROSCIENCE, 2021, 12 (24): : 4524 - 4534
  • [43] Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists
    Hamilton, JR
    Frauman, AG
    Cocks, TM
    CIRCULATION RESEARCH, 2001, 89 (01) : 92 - 98
  • [44] Protease-Activated Receptor-4 (PAR4) Activation: Evidences for Its Role and Activation in the Pathogenesis of Colitis and in Inflammatory Bowel Diseases
    Rousset, Perrine
    Cenac, Nicolas
    Balz-Hara, Daniela
    Asfaha, Samuel
    Ferraz, Jose G.
    Beck, Paul L.
    Panaccione, Remo
    Selves, Janick
    Alric, Laurent
    Vinel, Jean-Pierre
    Vergnolle, Nathalie
    GASTROENTEROLOGY, 2009, 136 (05) : A110 - A110
  • [45] Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides
    Hollenberg, MD
    Saifeddine, M
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2001, 79 (05) : 439 - 442
  • [46] Activation of protease-activated receptor (PAR) 1 by frog trefoil factor (TFF) 2 and PAR4 by human TFF2
    Yong Zhang
    Guoyu Yu
    Yanjie Wang
    Yang Xiang
    Qian Gao
    Ping Jiang
    Jie Zhang
    Wenhui Lee
    Yun Zhang
    Cellular and Molecular Life Sciences, 2011, 68 : 3771 - 3780
  • [47] Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects
    Chackalamannil, Samuel
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (18) : 5389 - 5403
  • [48] Activation of protease-activated receptor (PAR) 1 by frog trefoil factor (TFF) 2 and PAR4 by human TFF2
    Zhang, Yong
    Yu, Guoyu
    Wang, Yanjie
    Xiang, Yang
    Gao, Qian
    Jiang, Ping
    Zhang, Jie
    Lee, Wenhui
    Zhang, Yun
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2011, 68 (22) : 3771 - 3780
  • [49] Selective Platelet Protease-Activated-Receptor (PAR)1 and PAR4 Mediated Thrombin Desensitisation in the Elderly is Correlated With Inflammation and Chronic Thrombin Receptor Stimulation
    Gnanenthiran, Sonali R.
    Pennings, Gabrielle
    Reddel, Caroline
    Campbell, Heather
    Hamilton, Justin
    Chen, Vivien
    Kritharides, Leonard
    CIRCULATION, 2020, 142
  • [50] Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354
    Wen, Wandong
    Young, Summer E.
    Duvernay, Matthew T.
    Schulte, Michael L.
    Nance, Kellie D.
    Melancon, Bruce J.
    Engers, Julie
    Locuson, Charles W., II
    Wood, Michael R.
    Daniels, J. Scott
    Wu, Wenjun
    Lindsley, Craig W.
    Hamm, Heidi E.
    Stauffer, Shaun R.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (19) : 4708 - 4713
12345